Operating plan details commitment and development schedule for the next four years of one of Central Europe's largest untapped natural resources Vancouver, British Columbia--(Newsfile Corp. - March 5, ...
FDA accepted NDA for zidesamtinib for the treatment of TKI pre-treated patients with advanced ROS1-positive NSCLC; PDUFA target action date of September 18, 2026 NDA submission for neladalkib in TKI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results